In with 600... Buyout here is triple digits per share - trov had to prove safety to overcome the fear of deadly side effects brought by the older generation of these drugs (that got fda approved and wildly celebrated until side effects emerged)... Safety is proven - they want a higher dose!
Years in the making and typical biotech drama to scare off all but the strongest hands... This could be the time for (re)entry... 100x potential, 10x easy if the market decides to accumulate prior to a buyout (I think they will... This sleeper is about to awaken).
This is all I can risk (plus 20%), holding and waiting.
News 
Market Data 
Discover 
